Title: Chapter 26: Neuronal and astroglial monoamine oxidase: pharmacological implications of specific MAO-B inhibitors
Abstract: Publisher Summary Monoamine oxidases (MAOs) catalyze the deamination of monoamine neurotransmitters and neuromodulators, as well as of various exogenous bioactive monoamines. Two types of MAO— namely, A and B has been discovered. The two enzymes are heterogeneously distributed in different tissues. In the brain, MAO-A is the predominant form of enzyme within dopaminergic neurons, and both MAO-A and B are located in astroglial cells. A large number of MAO inhibitor, such as phenelzine and tranylcypromine, are used as antidepressant agents. The application of these latter, nonselective, irreversible, MAO inhibitor antidepressants is limited because they can cause a number of adverse effects, such as hepatotoxicity and severe hypertension, which follows from the ingestion of tyramine-rich foods and drinks. (-) -Deprenyl, a classical irreversible MAO-B inhibitor, is shown to possess antidepressant activity. Its remarkable effects in the treatment of Parkinsonism have attracted attention only lately. It was first used in conjunction with L-Dopa in the treatment of Parkinsonism.
Publication Year: 1992
Publication Date: 1992-01-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 7
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot